Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Peptides

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.peptides.2010.04.026PMID 20452383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats.

  2010cited by this paper
• Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.

  2009cited by this paper
• Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.

  2009cited by this paper
• Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction

  2008cited by this paper
• Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure.

  2008cited by this paper
• Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.

  2008cited by this paper
• Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

  2008cited by this paper
• Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

  2007cited by this paper
• Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

  2006cited by this paper
• Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

  2006cited by this paper
• Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

  2005cited by this paper
• Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

  2005cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Echocardiographic assessment of global ventricular function using the myocardial performance index in rats with hypertrophy.

  2004cited by this paper
• Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

  2004cited by this paper
• Plasma concentration of urotensin II is raised in hypertension

  2004cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling.

  2003cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Tissue Angiotensin-Converting Enzyme Activity Plays an Important Role in Pressure Overload–Induced Cardiac Fibrosis in Rats

  2002cited by this paper
• Left and right coronary circulation in left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition.

  2002cited by this paper
• Reduction in Myocardial Collagen Cross-Linking Parallels Left Ventricular Dilatation in Rat Models of Systolic Chamber Dysfunction

  2001cited by this paper
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy.

  2000cited by this paper
• Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.

  1999cited by this paper
• Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide.

  1998cited by this paper
• Differential changes in sympathetic activity in left and right ventricles in congestive heart failure after myocardial infarction.

  1997cited by this paper
• Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis.

  1990cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper

• The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure

  2020cites this paper
• A hasonló fokú fiziológiás és patológiás balkamra-hipertrófia különböző in vivo hemodinamikai következményekhez vezet

  2018cites this paper
• Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress

  2018cites this paper
• A novel urotensin II receptor antagonist, KR‐36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure

  2017cites this paper
• Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway.

  2016cites this paper
• Physiological and pathological left ventricular hypertrophy of comparable degree is associated with characteristic differences of in vivo hemodynamics.

  2016cites this paper
• Changes in cardiac structure and function in a modified rat model of myocardial hypertrophy

  2016cites this paper
• The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy

  2015cites this paper
• Alterations in cardiac structure and function in a modified rat model of myocardial hypertrophy

  2014cites this paper
• Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways.

  2014cites this paper
• Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction.

  2013cites this paper
• The effect of polymer degradation time on functional outcomes of temporary elastic patch support in ischemic cardiomyopathy.

  2013cites this paper
• The Uremic Toxin Adsorbent AST-120 Abrogates Cardiorenal Injury Following Myocardial Infarction

  2013cites this paper
• Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome.

  2012cites this paper
• expression: implications for cardiorenal syndrome renal interstitial fibrosis, and increases renal KIM-1 Myocardial infarction impairs renal function, induces

  2012cites this paper
• Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK.

  2012cites this paper
• Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl Sulfate

  2011cites this paper
• EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy

  2011cites this paper